BioSpace News Archive

Deciphera Pharmaceuticals, Inc. announced that it intends to offer and sell $125,000,000 of shares of its common stock in an underwritten public offering.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that management will participate in the following investor conferences.

CANbridge Pharmaceuticals, Inc. (1228.HK) announced that the first patient has been dosed in the Phase 2 part of the ongoing CAN103 Phase 1/2 trial in treatment-naïve patients with Gaucher disease (GD) Types I and III in China.

bluebird bio, Inc. announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions.

Ascentage Pharma and Innovent Biologics, Inc., announced that the novel drug olverembatinib has been included into the China 2022 National Reimbursement Drug List（NRDL), for the treatment of T315I-mutant chronic-phase chronic myeloid leukemia and accelerated-phase CML.

Krystal Biotech, Inc. announced today that the European Commission has granted orphan designation for KB407 for the treatment of Cystic Fibrosis (CF).

Orthogen AG , a leader in molecular medicine, announces U.S. Food and Drug Administration (FDA) approval of an Investigational Device Exemption (IDE) for the company’s proprietary technology, Orthogen® Device (OD).

EVOQ Therapeutics today announced the advancement of their ongoing license and collaboration agreement with Amgen for the discovery and development of novel therapeutics including the receipt of a milestone payment and expansion of the scope of collaboration to include a total of three indications in autoimmune disorders.

Teon Therapeutics today announced that it has entered into the clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada), a leader in immuno-oncology (IO).

SciSparc Ltd. today announced it has been granted an approval by the Soroka University Medical Center (“Soroka Medical Center”) to conduct its clinical study for SCI-210 in patients suffering from autism spectrum disorder (“ASD”).